Multiplex metabolic pathway engineering of Monascus pilosus enhances lovastatin production
Applied Microbiology and Biotechnology · 2023-11 · 107 (21) · 6541-6552
DOI: 10.1007/s00253-023-12747-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Microbiology and Biotechnology, online erschienen am 06.09.2023. Verfasst von Xiaokun Hong und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Biological Science and Engineering, Fuzhou University, Fuzhou, 350116, Fujian, China. Hauptthemen laut MEDLINE: Monascus, Lovastatin, Metabolic Engineering, Metabolic Networks and Pathways. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Fujian Province.
Abstract (Originalsprache)
Monascus sp. is an important food microbial resource with the production of cholesterol-lowering agent lovastatin and other healthy metabolites. However, the mycotoxin citrinin naturally produced by Monascus sp. and the insufficient productivity of lovastatin limit its large-scale use in food industry. The aim of this paper is to modify a lovastatin-producing strain Monascus pilosus GN-01 through metabolic engineering to obtain a citrinin-free M. pilosus strain with higher yield of lovastatin. The citrinin synthesis regulator gene ctnR was firstly disrupted to obtain GN-02 without citrinin production. Based on that, the lovastatin biosynthesis genes (mokC, mokD, mokE, mokF, mokH, mokI, and LaeA) were, respectively, overexpressed, and pigment-regulatory gene (pigR) was knocked out to improve lovastatin production. The results indicated ctnR inactivation effectively disrupted the citrinin release by M. pilosus GN-01. The overexpression of lovastatin biosynthesis genes and pigR knockout could lead higher contents of lovastatin, of which pigR knockout strain achieved 76.60% increase in the yield of lovastatin compared to GN-02. These studies suggest that such multiplex metabolic pathway engineering in M. pilosus GN-01 is promising for high lovastatin production by a safe strain for application in Monascus-related food. KEY POINTS: • Disruption of the regulator gene ctnR inhibited citrinin production of M. pilosus. • Synchronous overexpression of biosynthesis gene enhanced lovastatin production. • pigR knockout enhanced lovastatin of ΔctnR strain of M. pilosus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Biological Science and Engineering, Fuzhou University, Fuzhou, 350116, Fujian, China.
- College of Biological Science and Engineering, Fuzhou University, Fuzhou, 350116, Fujian, China. xuxinqi@fzu.edu.cn.
- College of Biological Science and Engineering, Fuzhou University, Fuzhou, 350116, Fujian, China. ljuan@fzu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province
Zitieren
APA
Hong, X., Guo, T., Xu, X., & Lin, J. (2023). Multiplex metabolic pathway engineering of Monascus pilosus enhances lovastatin production. Applied Microbiology and Biotechnology, 107(21), 6541-6552. https://doi.org/10.1007/s00253-023-12747-2
Vancouver
Hong X, Guo T, Xu X, Lin J. Multiplex metabolic pathway engineering of Monascus pilosus enhances lovastatin production. Applied Microbiology and Biotechnology. 2023;107(21):6541-6552. doi:10.1007/s00253-023-12747-2
BibTeX
@article{Hong2023,
author = {Hong, Xiaokun and Guo, Tianlong and Xu, Xinqi and Lin, Juan},
title = {Multiplex metabolic pathway engineering of Monascus pilosus enhances lovastatin production},
journal = {Applied Microbiology and Biotechnology},
year = {2023},
volume = {107},
number = {21},
pages = {6541--6552},
doi = {10.1007/s00253-023-12747-2}
}
EUVIMED